Skip to main content
    R

    RenovoRx Inc (RNXT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    +0.09 (+8.91%)

    Market Cap: $50.18M

    Last updated: Nov 17, 2026 at 4:29 PM ET

    RenovoRx Inc (RNXT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    RenovoRx (RNXT) has a market cap of $50.18M and an enterprise value of $39.78M. It kept -469.02% of revenue as net income over the last 12 months. Revenue grew 199.14% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 20.73% below the market cap, as cash exceeds debt.

    Market Cap$50.18M
    Enterprise Value$39.78M
    Latest price (Nov 17, 2026)$1.04

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.90% in the quarter ended Sep 30, 2026 and grew 39.01% a year over 2 years.

    Shares Outstanding48.19M
    Shares Change (YoY)+31.51%
    Shares Change (QoQ)+1.90%
    Share Count Growth (2Y CAGR)+39.01%

    Valuation Ratios

    Sales and book value multiples are 18.1x and 5.4x.

    P/S Ratio18.1x
    Forward P/S13.0x
    P/B Ratio5.4x

    Price Statistics

    The stock is up 38.67% over 52 weeks and trades 25.71% below its 50-day average.

    Beta (1Y)1.59
    52-Week Change+38.67%
    1-Month Change-10.34%
    3-Month Change-20.91%
    6-Month Change+29.05%
    5-Year Change-74.32%
    Total Return (1Y)+38.67%
    Total Return (5Y CAGR)-30.55%
    Max Drawdown (1Y)-62.11%
    Max Drawdown (3Y)-68.01%
    Sharpe Ratio (1Y)0.35
    Correlation with SPY (1Y)0.27
    50-Day Average$1.40
    200-Day Average$1.11
    52-Week Range$0.73 to $2.59
    RSI (14 Days)38.0
    Average Volume (20 Days)463.72K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.65x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.65x
    Quick Ratio5.49x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -140.24% and return on assets is -104.69% over the last 12 months.

    Return on Equity (ROE)-140.24%
    Return on Assets (ROA)-104.69%
    Asset Turnover0.23x
    Inventory Turnover1.22x
    Receivables Turnover5.10x
    Cash Conversion Cycle-373 days

    Scores

    RNXT has an Altman Z-Score of -0.88, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-0.88
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $2.78M over the last 12 months.

    Revenue$2.78M
    Revenue Growth (YoY)+199.14%
    Gross Profit$2.33M
    Operating Income-$13.58M
    Pretax Income-$13.02M
    Net Income-$13.02M
    Reported EPS (TTM)-$0.28

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 74.60% of the $12.44M in total assets.

    Cash and Equivalents$10.40M
    Total Debt$0
    Net Cash$10.40M
    Net Cash Per Share$0.22
    Working Capital$9.72M
    Shareholder Equity$9.28M
    Book Value Per Share$0.19
    Total Assets$12.44M
    Total Liabilities$3.15M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $90.00K of capital spending, operating cash flow left -$12.22M of free cash flow.

    Operating Cash Flow-$12.13M
    Capital Expenditures$90.00K
    Free Cash Flow-$12.22M
    FCF Per Share-$0.27
    Depreciation and Amortization$12.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -489.05%.

    Gross Margin84.04%
    Operating Margin-489.05%
    Pretax Margin-469.02%
    Net Margin-469.02%
    FCF Margin-440.38%

    Dividends and Yields

    RNXT does not pay a dividend.

    Buyback Yield-17.94%
    Shareholder Yield-17.94%

    Peer Position

    Against 7 similar companies, RNXT has the 5th highest P/S.

    P/S Ratio18.1x vs 24.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+199.14% vs +7.21% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 205.70% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+205.70%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RNXT

    What is RNXT's market cap?

    RenovoRx has a market cap of $50.18M. Its enterprise value, which adds debt and subtracts cash, is $39.78M.

    How many shares of RNXT are outstanding?

    RenovoRx has 48.19M shares outstanding. The count is up 31.51% from a year earlier.

    Does RNXT pay a dividend?

    No. RenovoRx does not pay a dividend.

    How much debt does RNXT have?

    RenovoRx has $0 of total debt and $10.40M of cash and equivalents, a net cash position of $10.40M.